Catheter Precision, Inc. announced on May 6, 2025, that its 82% owned subsidiary has completed the acquisition of certain heart failure related assets of Cardionomic, Inc. This acquisition follows a definitive agreement entered into in April.
The acquired assets are related to a late-stage treatment in development for acute decompensated heart failure. This strategic move expands Catheter Precision's product portfolio beyond its initial electrophysiology focus.
The completion of this acquisition signifies Catheter Precision's commitment to diversifying its pipeline and addressing broader needs within the cardiac market. These assets, while late-stage, require further development and regulatory approval before commercial use.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.